TY  - JOUR
AU  - Rodriguez-Gil, Alfonso
AU  - Escamilla-Gomez, Virginia
AU  - Nufer, Melanie
AU  - Andujar-Sanchez, Felix
AU  - Lopes-Ramos, Teresa
AU  - Bejarano-Garcia, Jose Antonio
AU  - Garcia-Guerrero, Estefania
AU  - Calderon-Cabrera, Cristina
AU  - Caballero-Velazquez, Teresa
AU  - Garcia-Calderon, Clara Beatriz
AU  - Hernandez-Diaz, Paola
AU  - Reguera-Ortega, Juan Luis
AU  - Rodriguez-Torres, Nancy
AU  - Martinez-Cibrian, Nuria
AU  - Rodriguez-Barbosa, Jose Ignacio
AU  - Villadiego, Javier
AU  - Perez-Simon, Jose Antonio
PY  - 2022
DO  - 10.1038/s41598-022-12407-x
UR  - http://hdl.handle.net/10668/19610
T2  - Scientific reports
AB  - Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined...
LA  - en
PB  - Nature Publishing Group
KW  - Bone marrow transplantation
KW  - Haematological cancer
KW  - Animals
KW  - Disease Models, Animal
KW  - Graft vs Host Disease
KW  - Mice
KW  - Nitriles
KW  - Pyrazoles
KW  - Pyrimidines
KW  - T-Lymphocytes, Regulatory
TI  - Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.
TY  - research article
VL  - 12
ER  -